We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.62%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.2B
AUM Growth
+$36.4M
Cap. Flow
+$49.6M
Cap. Flow %
2.25%
Top 10 Hldgs %
26.49%
Holding
159
New
12
Increased
46
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$23.1M
2
SYK icon
Stryker
SYK
+$19.3M
3
HOLX
Hologic
HOLX
+$13.4M
4
ZBH icon
Zimmer Biomet
ZBH
+$11.4M
5
MOH icon
Molina Healthcare
MOH
+$10.4M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$27.5M
2
DHR icon
Danaher
DHR
+$19.3M
3
MDT icon
Medtronic
MDT
+$19.2M
4
BCR
CR Bard Inc.
BCR
+$18.4M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.16%
2 Financials 2.8%
3 Consumer Discretionary 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
126
Seres Therapeutics
MCRB
$48.4M
$2.23M 0.1%
11,000
– –
RYTM icon
127
Rhythm Pharmaceuticals
RYTM
$7.96B
$2.08M 0.09%
+71,500
New +$1.89M
CGEN icon
128
Compugen
CGEN
$228M
$2.06M 0.09%
825,000
– –
CDTX
129
DELISTED
Cidara Therapeutics
CDTX
$2.04M 0.09%
15,000
– –
CORV
130
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$1.86M 0.08%
1,200,000
– –
DBVT
131
DBV Technologies
DBVT
$847M
$1.8M 0.08%
7,300
– –
SCYX icon
132
SCYNEXIS
SCYX
$52M
$1.76M 0.08%
9,500
– –
ALPN
133
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.68M 0.08%
150,000
– –
ATYR
134
aTyr Pharma
ATYR
$50.1M
$1.66M 0.08%
33,929
– –
PRTA icon
135
CALL
Prothena Corp
PRTA
$450M
$937K 0.04%
+25,000
New +$1.27M
CHMA
136
DELISTED
Chiasma, Inc. Common Stock
CHMA
$893K 0.04%
525,000
+32,500
+7% +$68.2K
INFI
137
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$548K 0.02%
270,000
– –
OREX
138
DELISTED
Orexigen Therapeutics, Inc.
OREX
$213K 0.01%
165,300
– –
DARE icon
139
Dare Bioscience
DARE
$21M
$135K 0.01%
5,208
– –
ACAD icon
140
Acadia Pharmaceuticals
ACAD
$5.03B
– –
-182,000
Closed -$6.86M
DHR icon
141
Danaher
DHR
$144B
– –
-253,800
Closed -$19.3M
KALA icon
142
KALA BIO
KALA
$14.5M
– –
-10
Closed -$571K
MDT icon
143
Medtronic
MDT
$112B
– –
-247,364
Closed -$19.2M
REGN icon
144
Regeneron Pharmaceuticals
REGN
$80.8B
– –
-16,000
Closed -$7.15M
TNDM icon
145
Tandem Diabetes Care
TNDM
$1.56B
– –
-56,250
Closed -$411K
LUMO
146
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-8,056
Closed -$738K
MYOK
147
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-40,000
Closed -$1.71M
EGLT
148
DELISTED
Egalet Corporation
EGLT
– –
-300,000
Closed -$384K
ANTH
149
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-107,630
Closed -$155K
KITE
150
DELISTED
Kite Pharma, Inc.
KITE
– –
-68,000
Closed -$12.2M
3 4 5
6
7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rock Springs Capital Management held 159 positions worth $2.2B, up 1.7% from $2.17B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q4 2017 filing shows 12 new, 46 increased, 21 reduced and 14 closed positions. Its largest new stake was Teleflex: 91,750 shares worth $22.8M. The largest sale was Aetna Inc, an estimated $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2017 buy was Teleflex: 91,750 shares worth $22.8M.
  • Rock Springs Capital Management added most to Zimmer Biomet in Q4 2017, an estimated $11.4M increase.
  • Rock Springs Capital Management's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $27.5M.
  • Rock Springs Capital Management fully exited Danaher in Q4 2017, selling an estimated $19.3M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.2B portfolio in Q4 2017.
  • Rock Springs Capital Management opened 12 new positions and closed 14 in Q4 2017.
  • Rock Springs Capital Management's portfolio value rose 1.7% quarter-over-quarter to $2.2B.

Based on Rock Springs Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.